Longeveron Selects Clinical Research Organization for Phase 2 Alzheimer’s Disease Trial
November 5, 2021 – Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening...
Read More













